Potential Use of anti-IgE in the Treatment of Lupus Nephritis


Systemic lupus erythematosus (SLE) is a multi-organ inflammatory disease characterized by a significant morbidity and mortality related to both disease evolution as well as therapeutic side effects. At least half of SLE patients develop lupus nephritis.

The inventors have used a Lyn -/- mouse model that develops an autoimmune disease exhibiting some features of human SLE. Using this model the inventors identified basophils and self-reactive IgEs as important components in the development of autoantibody-mediated kidney disease. The inventors found that depletion of basophils or the absence of IgE causes a considerable reduction in autoantibody production and preserves kidney function in the Lyn -/- mice. The inventors' work demonstrates that IgE immune complexes can activate basophils and that removal of self-reactive IgEs that form functional circulating immune complexes prevents kidney disease. Further, the inventors have shown that basophils are contributors to the production of the self-reactive antibodies that cause lupus-like nephritis in the Lyn -/- mice. Accordingly, reducing circulating IgE levels or reducing basophil activation may be of therapeutic benefit.

Potential Commercial Applications: Competitive Advantages:
Further research and development of therapeutic approach to treat lupus nephritis. Current treatment of lupus has not advanced for many years. This finding is of importance for its potential in advancing treatment of the disease.


Development Stage:
  • Early-stage
  • Pre-clinical


Inventors:

Juan Rivera (NIAMS)  ➽ more inventions...

Nicolas Charles (NIAMS)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 9,657,292 issued 2017-05-23
U.S. Pat: 10,017,762 issued 2018-07-10
US Application No. 15/498,202
US Application No. 16/030,185

Publications:
Charles N, et al. PMID 20512127
Brightbill HD, et al. PMID 20458139
Mack M, et al. PMID 19692999
Busse W, et al. PMID 11496232

Collaboration Opportunity:

The National Institute of Arthritis and Musculoskeletal and Skin Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the technology for the use of anti-IgE in the treatment of Lupus Nephritis. For collaboration opportunities, please contact Cecilia Pazman at pazmance@mail.nih.gov.


Licensing Contact:
Benfeard Williams, Ph.D.
Email: benfeard.williams@nih.gov
Phone: 301-435-4507

OTT Reference No: E-216-2010-0
Updated: Mar 27, 2012